Supporting the therapeutic role of CHP in DMD‐associated cardiovascular dysfunction, tissue remodeling, and Rho‐related pathways were down‐regulated by the treatment (Figure 4I). The gene discussed is RHO; the disease is Duchenne muscular dystrophy.